Echo Therapeutics (ECTE) Stock Price, News & Analysis

Company Overview

Echo Therapeutics Inc. is a developer of non‐invasive biosensing platforms, with a particular focus on continuous glucose monitoring for diabetes management. The company’s core technology utilizes reverse iontophoresis to extract interstitial fluid through the skin, enabling real‐time glucose measurements without the need for fingerstick blood tests. Over its history, Echo Therapeutics has sought FDA clearance for wearable monitoring devices designed to deliver actionable data to patients and healthcare providers.

Echo Therapeutics’ first commercial product, the GlucoWatch® Biographer, received FDA approval in the early 2000s and represented one of the initial attempts to bring transdermal glucose sensing to market. Although the company faced regulatory and market challenges with its first‐generation device, it continued to refine its sensing platform through research collaborations and strategic partnerships. Echo Therapeutics has historically been based in the United States and has pursued distribution and reimbursement pathways in North America and select international markets.

Building on its proprietary transdermal sensing technology, Echo Therapeutics is exploring applications beyond glucose monitoring, including pharmacokinetic studies and adherence tracking for a variety of therapeutic areas. While information on its current product pipeline and executive team is limited, the company remains focused on advancing minimally invasive diagnostic solutions. Echo Therapeutics trades on the OTC Markets under the symbol ECTE, where it engages with investors regarding its ongoing research and development efforts.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.28
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ECTE Stock Analysis - Frequently Asked Questions

How have ECTE shares performed this year?

Echo Therapeutics' stock was trading at $0.0002 on January 1st, 2025. Since then, ECTE shares have increased by 0.0% and is now trading at $0.0002.

How were Echo Therapeutics' earnings last quarter?

Echo Therapeutics Inc. (OTCMKTS:ECTE) announced its quarterly earnings results on Friday, August, 12th. The medical device company reported ($0.82) earnings per share for the quarter.

How do I buy shares of Echo Therapeutics?

Shares of ECTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Echo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Echo Therapeutics investors own include DexCom (DXCM), Rexahn Pharmaceuticals (REXN), Acer Therapeutics (ACER), Athersys (ATHX), Blackstone Strategic Credit 2027 Term Fund (BGB), Biocept (BIOC) and BlackRock Science and Technology Trust (BST).

Company Calendar

• Last Earnings: 8/12/2016
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ECTE
• Previous Symbol: NASDAQ:ECTE
• CIK: 1031927
• Web: www.echotx.com
• Phone: (732) 201-4194
• Fax: 215-717-4109
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A